Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

CRISPR Therapeutics AG. (10/2/18). "Press Release: CRISPR Therapeutics to Present at the Chardan Genetic Medicines Conference". Zug & Cambridge, MA.

Organisations Organisation CRISPR Therapeutics AG (Nasdaq: CRSP)
  Group CRISPR Therapeutics (Group)
  Organisation 2 Chardan Capital Markets LLC
Products Product Chardan Genetic Medicines Conference 2018 New York
  Product 2 CRISPR gene editing technology
Index term Index term CRISPR Therapeutics–Chardan: investor conference, 201810 supply service CRISPR presents at Chardan Genetic Medicines Conference in New York
Persons Person Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
  Person 2 Kim, Susan (CRISPR Therapeutics 201809 Investor Relations)
     


CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer, will present at the Chardan Genetic Medicines Conference on Tuesday, October 9, 2018 at 11:30 am ET.

A live webcast of the Chardan presentation will be available on the "Events & Presentations" page in the Investors section of the company's website at https://crisprtx.com/events. A replay of the webcast will be archived on the company's website for 14 days following the presentation.


About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc.

CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.


CRISPR Investor Contact:
Susan Kim
susan.kim@crisprtx.com

CRISPR Media Contact:
Jennifer Paganelli
WCG on behalf of CRISPR
347-658-8290
jpaganelli@wcgworld.com

   
Record changed: 2018-10-13

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for CRISPR Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top